Peripheral blood progenitor cell mobilization practices vary significantly among institutions.
Effective mobilization regimens include growth factor alone, chemotherapy and growth factor …

Allogenic hematopoietic cell transplantation (HSCT) is typically the preferred curative
therapy for adult patients with acute myeloid leukemia, but its use has been reduced as a …

Large-scale production of human induced pluripotent stem cells (hiPSCs) by robust and
economic methods has been one of the major challenges for translational realization of …

Previous observations have reported controversial conclusions regarding cell dose and
survival endpoints after allogeneic hematopoietic stem cell transplantation (HSCT). We …

Mobilized peripheral blood is the most common graft source for allogeneic hematopoietic
stem cell transplantation following reduced-intensity conditioning. In assessing the effect of …

Higher infused total nucleated cell dose (TNC) in allogeneic bone marrow transplant (BMT)
with post-transplant cyclophosphamide (PTCy) is associated with improved overall survival …

The impact of infused CD34+ cell dose on outcomes after allogeneic hematopoietic stem
cell transplantation (alloHSCT) using standard graft-versus-host disease (GVHD) …

Human embryonic stem cells (hESCs) play an important role in regenerative medicine due
to their potential to differentiate into various functional cells. However, the conventional …

Human pluripotent stem cells (hPSCs) hold great promise for revolutionizing regenerative
medicine for their potential applications in disease modeling, drug discovery, and cellular …

To elucidate the impact of infused CD34+ cell doses on transplant outcome, we
retrospectively analyzed 851 adult patients who received peripheral blood stem cell …